Ayla Annac is an accomplished and entrepreneurial-minded executive. Annac is the CEO/President and Co-Founder of InvivoSciences, Inc. (IVS). (IVS) is a pre-clinical-stage biotech company developing therapies for cardiovascular and cardiometabolic diseases. IVS’s innovation is utilizing its predictive precision medicine technology platform, Kokordia™, combining patient-derived micro heart on a chip, NuHeart™, AI-assisted patient-stratification diagnostic technology, and automated instrumentation for precision medicine development. IVS201 is the company’s first drug development program targeting heart failure with preserved ejection fraction (HFpEF). www.invivosciences.com
Annac’s 23-year strategic business development experience in Fortune 500 companies and technology startups enabled the commercialization of IVS’s award-winning technologies for drug discovery and development. IVS’s initial technologies received Gold in the 2012 Edison Award and received Gold in the 2009 world’s best technologies Award in the state of Texas. Science Magazine also listed IVS among the honorable mentions awards.
In 2015, In-Business Magazine awarded Ms. Annac with a Women of Industry Award for her leadership contribution to biotech entrepreneurship. She was a scholar of the 2016 Goldman Sachs 10000 Small Business Program in Babson College, Tong BME Distinguished Entrepreneur Lecturer, and a scholarship recipient for the 2017 Springboard rare disease program. She was a Ted.com speaker Oct 2018 in London. https://www.youtube.com/watch?v=XXSxqGYnZ0Y&t=16s
She was invited to participate in GES2019 Netherland and invited in 2019 as a panel speaker at “Women’s Leadership in healthcare and its impact on Health Equity “at World Women Summit. Annac has served as a judge for the Wisconsin Governor’s Business Plan Competition in biotechnology, for UW Burill Business Plan Competition, and for UW Biomedical Engineering School. She resides in Madison, Wisconsin, married with two children.